Blinatumomab for MRD⁺ B-ALL: the evidence strengthens

Patrick Brown¹

Affiliations

PMID: 29622532
DOI: 10.1182/blood-2018-02-830364

Free article

Comment

Blinatumomab for MRD⁺ B-ALL: the evidence strengthens

Patrick Brown. Blood. 2018.

Free article

. 2018 Apr 5;131(14):1497-1498.

doi: 10.1182/blood-2018-02-830364.

Author

Patrick Brown¹

Affiliation

¹ Johns Hopkins University.

PMID: 29622532
DOI: 10.1182/blood-2018-02-830364

No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: The author declares no competing financial interests.

Comment on

Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia.
Gökbuget N, Dombret H, Bonifacio M, Reichle A, Graux C, Faul C, Diedrich H, Topp MS, Brüggemann M, Horst HA, Havelange V, Stieglmaier J, Wessels H, Haddad V, Benjamin JE, Zugmaier G, Nagorsen D, Bargou RC. Gökbuget N, et al. Blood. 2018 Apr 5;131(14):1522-1531. doi: 10.1182/blood-2017-08-798322. Epub 2018 Jan 22. Blood. 2018. PMID: 29358182 Free PMC article. Clinical Trial.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
- Silverchair Information Systems
Other Literature Sources
- scite Smart Citations

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Blinatumomab for MRD⁺ B-ALL: the evidence strengthens

Affiliation

Blinatumomab for MRD⁺ B-ALL: the evidence strengthens

Author

Affiliation

Conflict of interest statement

Comment on

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources